Medicofarma S.A.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2007-08-08
Share capital
21,000,000.00 PLN
Activity description

Medicofarma is a company specializing in contract manufacturing of pharmaceuticals and dietary supplements. It is the first Polish producer of a COVID-19 test, known as MediPAN-2G+ FAST COVID, which is recognized for its speed and sensitivity. The company also operates a Research and Development Laboratory to innovate in health protection and produce various pharmaceutical forms.

Registered address
ul. Sokołowska 9/U19, 01-142 Warszawa, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-67277-35262-WIUTS-13

Financials

Revenue history (in m)

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. 6 of 6 financial statements were filed late (the longest delay 181 days for 2019). All were audited by a statutory auditor.

  • 2025not filed
  • 202429/10/2025
  • 202301/08/2024
  • 202221/08/2023
  • 202113/12/2022
  • 202003/11/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.

Sector · Manufacturing5,231 / 33,822
Top 15%
Voivodeship · Mazowieckie8,370 / 142,204
Top 5.9%
Country · Poland28,723 / 496,474
Top 5.8%

Results vs industry

Revenue
This companyUSD 8.53mMedianUSD 913.43kAverageUSD 25.82m
Net profit
This companyUSD 3.16kMedianUSD 14.22kAverageUSD 2.77m
Operating costs
This companyUSD 7.26mMedianUSD 846.99kAverageUSD 21.42m
Assets
This companyUSD 29.34mMedianUSD 897.46kAverageUSD 31.52m

Public procurement

2 tenders recorded as contractor: 1 national ($33,109) and 1 EU ($215,735).

SubjectAmount
Repackaging and blinding of medicines containing the active substances pirfenidone and nintedanib
$215.7K
Supply of placebo and reference medicinal product in connection with the conduct of a non-commercial clinical trial
$33,109

Trademarks

The company holds 26 active trademarks registered with the Polish Patent Office. 22 marks have expired or were not registered. The first mark was filed in 2003.

MarkNumberClassesStatusProtected until
ENCOPIRIN (word)Z.5575565, 35Protected Jun 28, 2033
MediPAN-2G+ (word)Z.5170045, 10Protected Aug 10, 2030
FEVERINEX (word)Z.5139225Protected May 25, 2030
VIRUNAZON (word)Z.5139295Protected May 25, 2030
ADAROSTIN (word)Z.5136395Protected May 19, 2030
MarkProtected until
ENCOPIRIN (word)Jun 28, 2033
MediPAN-2G+ (word)Aug 10, 2030
FEVERINEX (word)May 25, 2030
VIRUNAZON (word)May 25, 2030
ADAROSTIN (word)May 19, 2030

Authorized Representatives

Marcin Adam Kuryłek age 56 – Attorney-in-fact (sole)
Cezary Robert Kilczewski age 61 – President of the Management Board

Manner of representation

Each member of the management board acting independently.

Supervisory board

Alicja Maria Jabłońska age 65 – Supervisory Board Member
Maciej Eustachiusz Szamborski age 80 – Supervisory Board Member
Marek Kazimierz Lubicz-Nowicki age 75 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2001-01-10.

  • mBank
    84 1140 1010 0000 5178 5500 1013
  • mBank
    90 1140 1010 0000 5178 5500 1002
  • mBank
    63 1140 1010 0000 5178 5500 1003

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

7 notices recorded in the Court and Commercial Gazette (MSiG).

Publication dateEvent
Feb 29, 2016Commercial Companies Code notice
Jun 22, 2015Shareholders' meeting convened
Jul 31, 2014Commercial Companies Code notice
Aug 6, 2013Shareholders' meeting convened
Feb 8, 2013Shareholders' meeting convened

Public aid

22 public aid cases recorded, with a total value of $3,337,909.

PurposeGross amount
Regional investment aid
$293.1K
De minimis aid (in accordance with Commission Regulation 2023/2831)
$1,092
De minimis aid (in accordance with Commission Regulation 2023/2831)
$68

European Funds

ProjectEU co-financing
Implementation of R&D results and launch of production of innovative dermocosmetics containing the patented 4-N-furfurylcytosine molecule.
$1.3M

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Exim Pharma sp. z o.o.
Przedsiębiorstwo Produkcyjno-Handlowe Ewa S.A.
Valentis Polska sp. z o.o.
Biofaktor sp. z o.o.
Ośrodek Badawczo-Produkcyjny Politechniki Łódzkiej Ichem sp. z o.o.
Wellmedica Hf sp. z o.o.
Nutramatic sp. z o.o.
Tantus sp. z o.o.
Bioactive T sp. z o.o.
Grand Medical Poland sp. z o.o.

Change history

DateEvent
2019-11-27Share capital increase
2019-08-21Share capital increase
2015-12-07Address change
2015-12-07PKD change
2013-04-12Share capital increase

FAQ

Last updated: 2026-03-22